Japan's Tokyo Ranks 19th in Global Drug Innovation Ecosystem, Ministry Calls for More Risk Capital

On the surface this is about Japanese pharma's ranking anxiety; underneath sits a big question tied to Taiwanese biotech investment and to global drug prices: when the United States pushes to cut drug prices, where does money flow, and where does it stop.

Hiroo Inoue, a senior METI official for commerce and services, put it plainly: to raise Japan's drug-discovery strength, the key is to "increase risk money." The uncomfortable reality he pointed to is the ranking. On a global index of drug-discovery ecosystems, Tokyo sits only 19th and Osaka 31st, while Beijing is 5th and Shanghai 6th, with Boston and San Francisco on top. Once called a "drug-discovery power," Japan now trails the U.S. and China in attracting early-stage capital and talent.

The thornier variable comes from America. In 2025, the Trump administration's "most favored nation" (MFN) drug-pricing policy aims to pull U.S. prices down to the lowest levels charged elsewhere. Inoue called this a "serious problem," because it could force price cuts even during patent protection, hitting the predictability drugmakers rely on to recoup research costs. For an industry that bets a decade and billions of dollars, predictability is the precondition for investment; when it falls, money pulls back. Japan's government wrote an MFN response into its "Basic Policy 2026," a sign this is no minor matter. A scale anchor: Japan's pharmaceutical market is the world's fourth largest, around 11 trillion yen.

For Taiwanese readers: the geography of biotech investment matters, as capital concentrates in Boston, San Francisco, and a fast-rising China, so "how deep is the risk capital" is itself a variable when picking stocks and locations. And MFN-style pricing policy is a global tailwind or headwind that hits U.S., European, and Japanese drugmakers alike. Watch whether Japan's tools to attract risk money actually land, and how forcefully the U.S. enforces MFN.